Tests that Measure 'Biological Age' Aren't Helpful for Tracking Your Health, Scientists Say

Why It Matters

The booming consumer market for biological‑age testing risks misinforming individuals and could be exploited by insurers, amplifying health inequities, while researchers continue to rely on these tools to uncover aging mechanisms.

Key Takeaways

• Dozens of epigenetic clocks exist, often yielding inconsistent results
• Short‑term factors like diet can swing biological age readings
• No gold‑standard method; saliva vs blood give different ages
• Tests are research tools, not approved medical diagnostics for individuals
• Insurers could misuse results, widening health disparities

Pulse Analysis

The allure of a single number that claims to capture how "old" your body really is has spurred a wave of direct‑to‑consumer epigenetic age tests. Companies price these kits anywhere from $30 to over $1,000, promising insights into longevity, disease risk, and lifestyle optimization. At their core, the tests analyze DNA methylation marks—chemical tags that shift as we age—and feed the data into statistical models known as epigenetic clocks. While the science behind these clocks is robust in large‑scale studies, translating that precision to a one‑off consumer test introduces a host of uncertainties.

Technical variability is the Achilles’ heel of individual‑level applications. Different clock algorithms target distinct biological pathways, and even the same algorithm can produce divergent ages when run on blood versus saliva samples. Short‑term influences—such as a recent illness, a high‑fat meal, or the time of day the sample is taken—can swing the estimated age by several years. Without an industry‑wide standard or regulatory oversight, consumers receive results that lack the reproducibility and clinical validation required for medical decision‑making, opening the door to confusion and potentially harmful health choices.

For researchers, however, epigenetic clocks remain a powerful lens for dissecting the aging process. Large cohort studies have linked slower epigenetic aging to calorie restriction, regular exercise, and adequate sleep, while experimental therapies like rapamycin show promise in reducing clock‑derived age at the group level. As the field matures, policymakers must grapple with how to prevent misuse—particularly by insurers who might adjust premiums based on a metric shaped by socioeconomic and environmental factors. Until standards are established and clinical relevance is proven, biological‑age tests should stay in the research realm, not the consumer health toolbox.